All News

FDG-PET uptake at baseline in GCA predicts future risk of future thoracic aneurysm In print here: https://t.co/2SQm18y6zP Could this help stratify aneurysmal screening? #ACR23 ABST1647 @RheumNow https://t.co/p1Dhkm2WTX

Association Between Vascular 18F-Fluorodeoxyglucose Uptake at Diagnosis and Cha…

It's OK to use TNFi in RA-ILD! VA study 1000+ pts using Target Trial Emulation framework: TNFi vs nonTNFi biologics/JAKi followed for 3 years. NO differences in respiratory hospitalizations or deaths or all cause mortality. abst#1582 #ACR23 #ACRbest @rheumnow https://t.co/aI2SmMrLPE

Wolfgang Schmidt presenting @eular_org large vessel vasculitis imaging recommendations at #ACR23, acknowledging @ACRheum on the way. Great to see a master (& a new ACR Master) navigate with clarity, uniting different sides of the Atlantic. @RheumNow https://t.co/hyAcX8GSWf

What do we see in GCA, with serial PET/CT after five years? In this Australian cohort: cranial uptake disappears extra-cranial uptake sometimes emerges (but not for pts on DMARDs) Still understanding the trajectory of smouldering activity @tonysammel #ACR23 ABST1645 @RheumNow https://t.co/mKB3mjBuBt

Factors predicting fatigue in RA differ by disease activity. Synovial lining hyperplasia and synovial lymphocytic inflammation on histology were key factors. @rheumnow #ACR23 session 13M148 https://t.co/yPBZX2Rxft

RA-ILD: the study that exonerates TNFi ? TNFi vs. other BioDMARDs/JAK do not increase risk of death or hospitalization over 1 and 3 yrs follow up. No subgroups stand out VHA cohort, 50% smokers No info on ILD patterns or disease trajectory ABST1582 @RheumNow #ACR23 https://t.co/frv16oRLqv

Lovering et al. Synergestic effect of RA and CVD on dementia risk. 35% increased risk RA, 89% increased risk RA+CVD. Abstr#1628 #ACR23 @RheumNow https://t.co/Brj8XrG2o4

#ClinicalPearl or #pathology pearl? Using synovial #biopsies to guide therapy in #RA #RCTs is a reality. But likely #fibrotic #phenotype won’t respond and #lympho_myeloid has more RA damage. #ACR23 session 13M140 #Precision #medicine #ACRbest ⁦@ACRheum⁩ ⁦@RheumNow⁩ https://t.co/DmI9dNpu8w

PET/CT real-world performance in GCA diagnosis, Sydney @tonysammel: comparable to other modalities can optimize for sen or spec based on managing equivocal results ?some steroid confounding but definitely one of 3 complementary imaging options for GCA #ACR23 ABST1646 @RheumNow https://t.co/FvdLMvpqEU

#ACR23 Abstr#1634 Promising therapy for two #Sjogren groups: 1 (high ESSDAI & ESSPRI) & 2 (low ESSDAI, high ESSPRI). Phase 2 RCT of Iscalimab (anti-CD40ab) showed more ISC-treated pts met the primary endpoint (ESSDAI and ESSPRI changes at WK24) vs PBO. Going to Phase 3 @RheumNow https://t.co/3bN3IS1zCO

@Dr_K presenting long COVID data from FORWARD RA. These pts had some symtoms before COVID!- More comorbidites, depression patient reported scores, fibromyalgia but no different DMRD use. PHQ8 and wodepread paid were the most important PROMs @RheumNow #ACR23 https://t.co/JaWc4oDnaI

Window of opportunity in PsA Higher time to diagnosis in -female -higher enthesitis -less swollen joints -lower CRP If diag > 52 wks, over 3 yrs Less MDA, less remission Worse HAS-DI, PSAID Same Rx progression No diff between <12 wk & 12-52 wk @RheumNow #ACR23 ABST1641 https://t.co/Ek1CDFwENg

#Precision #Medicine in RA RCTs. Treat w right drug at right time? Possible problems -sample variation on synovial #bx, some won’t respond ex fibrotic phenotype variable drug distribution/resistance. AI is helping to separate Pts #ACR23 ⁦@ACRheum⁩ ⁦@RheumNow⁩ 13M140 https://t.co/D7NxpM4YNw

Michaud et al. RA patients with long COVID had more fibromyalgia pre-COVID (41% vs 13%), higher rates of pain, depression, and worse PROs pre-COVID. Authors suggest long COVID may partially reflect pre-existing illness Abstr#1629 #ACR23 #ACRbest @RheumNow https://t.co/mrcGWrSD6c https://t.co/YiGCbvBDtn

Haberman et al. In PsA non-white patients have higher tender (but not swollen) joint counts, higher radiographic axial disease, worse skin disease. Women have higher RAPID-3 scores. Abstr#1639 #ACR23 @RheumNow https://t.co/4SL7FLzNuE https://t.co/sVwk1VaSLS

SGLT2 inhibitors compared to DPP4i may be better at reducing risk for MACE & renal progression in patients with SLE/LN and diabetes. SGLT2i risk for MACE (HR 0.69, 95% CI 0.48-0.99), and renal progression (HR 0.71, 95% CI 0.51-0.98). abst# 1579 #ACRbest #ACR23 @rheumnow

#ACR23 Abstr#1512 Can we improve trial design of Bcell depletion in #SLE? Feasibility RCT of RTX in organ specific MSK showed: a) feasible to use ultrasound & clinical as endpoints, b) new tool LAMDA is responsive, c)potential worsening before later improvement with RTX @RheumNow https://t.co/YmbUOWVdWS

Do you discuss HPV vax & cervical CA screening w/SLE & RA pts? In this study, more women w/SLE discussed cervical CA screening w/their rheums(33.3% vs. 11.4% p<0.01) & more likely to have persistent abn paps on ffup Similar HPV vax status for both grps #ACR23 ABST1356 @RheumNow https://t.co/Vbu8hbZ1uh

#ACR23 Abstr#1509 SLR & Meta-Analysis of RCTs in lupus nephritis (N=16 studies): -CNI (VOC/TAC/CyA) alone (OR 1.4) or combined MMF (OR 2.1) was assoc with CR vs SOC (MMF/Cyclo) -Less GI AEs & cytopenia in CNI Assuring data esp when cost is a hurdle for VOC @RheumNow #ACRBest https://t.co/9ScakIdXBN

Karpouzas et al. MTX reduces IHD in males but not females with RA. 4362 patients. 66% lower risk MACE and 55% lower risk any ischaemic CVE. Abstr#1627 #ACR23 @RheumNow https://t.co/MC4W0dinUv https://t.co/1hkBoawt4b

Topics

All News

Do you get our email newsletter?